Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies.

Peripheral blood progenitor cells (PBPC) were mobilized and harvested in 200 patients treated for non-Hodgkin's lymphoma (n = 148), Hodgkin's disease (n = 22) and multiple myeloma (n = 30). The variables predicting the collection of a minimal (>2.5 x 10(6)/kg) or a high (>10 x 10(6)/kg) CD34+ cell count were analysed.

High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation.

Optimal numbers of CD34(+) cells to be reinfused in patients undergoing peripheral blood progenitor cell (PBPC) transplantation after high-dose chemotherapy are still unknown. Hematologic reconstitution of 168 transplantations performed in patients with lymphoproliferative diseases was analyzed according to the number of CD34(+) cells reinfused. The number of days from PBPC reinfusion until neutrophil recovery (>1.

[Apheresis tolerance and acceptability in the child weighing 30 kg or less, with the exception of infants].

Over the ten past years, we performed 336 apheresis among 51 children who were 19 months to 15 years old (10 to 30 kg body weight). 3 types of apheresis were carried out. 14 red blood cell exchange, 293 plasma exchanges and 29 peripheral blood stem cell collections (CSP).

Restoration of high immunoglobulin gene expression in chronic lymphoid leukemia: a possible application for gene therapy.

In this study, using interleukin-2 and gamma interferon, we first induced the differentiation into plasma cells of primary chronic lymphoid leukemic B cells from patients whose T cells failed to produce interleukin-2. We next demonstrated that these malignant primary B lymphocytes (i.e.

Successful treatment of acquired factor VIII antibody by extracorporeal immunoadsorption.

We report the successful treatment of a 59-year-old woman with acquired factor VIII inhibitor. The patient who had an extensive leg hematoma with a resultant neurologic defect was treated with extracorporeal immunoadsorption (IA) using protein A-Sepharose, factor VIII concentrates, azathioprine, and methyl-prednisolone. Extracorporeal IA reduced the titers of the inhibitor so that factor VIII concentrates could raise the level of factor VIII coagulant activity and stop the bleeding.

[Intensive immunosuppression in progressive multiple sclerosis. An open study comparing 3 groups: cyclophosphamide, cyclophosphamide-plasmapheresis and control subjects. Results after 3 years].

Three groups of 10 patients each with multiple sclerosis (MS) in a progressive phase were openly matched on the basis of age and invalidity (DSS Kurtzke). Variance analysis showed no significant difference between them for the main MS features. Group 1 received cyclophosphamide for 3 weeks (mean total dose: 152 mg/kg) with methylprednisolone (mean total dose: 2.

Transplant of rhesus-positive bone marrow in a rhesus-negative woman having anti-rhesus D alloantibodies.

A woman affected by acute myeloblastic leukemia was grafted with HLA A, B and D compatible rhesus-positive bone marrow from her brother. Before grafting, she had anti-D alloantibodies (1/512 IAT, 2.9 micrograms/ml).